• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB
Click for more information
0.00% 0.9¢

PATRYS LIMITED - Charts / Financials

Market Cap $18.51M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 18.55pm 25/04/2024 (20 minute delay) ?
Day
Open 0.9¢   Day High 0.9¢   Day Low 0.9¢
Daily Volume 455777
Bids   Sellers
Number Price Volume   Number Price Volume
12 0.8¢ 2423758   2 0.9¢ 1557178

Directors & Senior Management

Dr. Charmaine Gittleson Chairman of the Board
Dr. James A. Campbell Chief Executive Officer, Managing Director, Executive Director
Ms. Valentina Dubljevic Vice President - Research and Development
Dr. Rebecca Tunstall Vice President - Corporate Development
Dr. Deanne Greenwood Vice President - Business Development & Intellectual Property
Mr. Stefan Ross Company Secretary
Mr. Michael Stork Non-Executive Deputy Chairman of the Board

Data source: Refinitiv

(20min delay)
Last
0.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $18.51M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $4.102K 455.7K

Buyers (Bids)

No. Vol. Price($)
12 2423758 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 1557178 2
View Market Depth
Last trade - 13.26pm 25/04/2024 (20 minute delay) ?

Top Stories

High grade sniffs in Africa push Mako shares up 14%

Mako Gold Ltd (ASX: MKG) has seen its shares jump above 14 percent on news that it has discovered a high grade zone with grades of 76 grams per tonne at its 868,000-ounce Napié Project in Côte d’Ivoire.Shares rose 14.28 percent to 16 cents on Wednesday, as the exploration company ...
Aus inflation read of 3.6% spooks ASX – before quickly returning to green Australian inflation has come in mixed with an increase of 1% in the March quarter, but a decline from 4.1% in the December quarter.
Lithium Universe eyes hydropower setup for greener battery metals Lithium Universe announced it has made an application in Canada for renewable electricity to power its lithium carbonate plant.
Unith wraps up Q1 with $5M in cash as digital humans evolve Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But the bigger story is how good its digital humans are getting.
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.